King, Rebecca L. http://orcid.org/0000-0002-7132-0226
Gupta, Alia
Kurtin, Paul J. http://orcid.org/0000-0003-2427-5837
Ding, Wei http://orcid.org/0000-0001-9811-4601
Call, Timothy G.
Rabe, Kari G. http://orcid.org/0000-0002-7313-1875
Kenderian, Saad S. http://orcid.org/0000-0003-2767-3830
Leis, Jose F.
Wang, Yucai http://orcid.org/0000-0002-1576-8341
Schwager, Susan M.
Slager, Susan L. http://orcid.org/0000-0002-5173-4712
Kay, Neil. E. http://orcid.org/0000-0002-5951-5055
Koehler, Amber
Ansell, Stephen M. http://orcid.org/0000-0003-1244-6758
Inwards, David J.
Habermann, Thomas M.
Shi, Min http://orcid.org/0000-0002-5741-4293
Hanson, Curtis A.
Howard, Matthew T.
Parikh, Sameer A. http://orcid.org/0000-0002-3221-7314
Article History
Received: 14 September 2021
Revised: 6 January 2022
Accepted: 11 January 2022
First Online: 28 January 2022
Competing interests
: SAP: Research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which Sameer A. Parikh is a principal investigator (these funds are unrelated to the work presented in this manuscript). Sameer A. Parikh has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithKline, Innate Pharma, Adaptive Biotechnologies, and AbbVie (he was not personally compensated for his participation). NEK: Research funding from Acerta Pharm, Pharmacyclics, MEI Pharma, and Tolero. He is on a data safety monitoring committee for Agios Pharm, Celgene, Sunesis, Cytomx Therapeutics, MorphoSys, Rigel Pharmaceuticals, and Juno Therapeutics. He is on an advisory Board for AstraZeneca, Cytomx Therapeutics, Pharmacyclics Dava Oncology, Acerta Pharma BV, and Juno Therapeutics. WD: Research funding from Merck and DTRM. Advisory board: Merck and Octapharma (no personal compensation). YW: Research funding (to the institution) from Incyte, InnoCare, Novartis, and Genentech. SSK: patents and royalties in the field of CART cell therapy from Novartis, Humanigen, Mettaforge, and Morphosys. Research Funding: Novartis, Kite/Gilead, Juno/BMS, Humanigen, Morphosys, Lentigen, Tolero, Sunesis, and LeahLabs. Advisory Board: Kite, Juno, and Humanigen. Data Safety Monitoring Board: Humanigen. TMH: is on data monitoring committees for Seagen and Tess Therapeutics. TMH is a member of the Scientific advisory boards for Lilly, Morphosys, and Incyte. TMH receives no personal income from these activities. RLK: Research funding (to the institution) from Bristol-Myers Squibb/Celgene. The remaining authors have no conflicts of interest to declare relative to this work.